<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04118088</url>
  </required_header>
  <id_info>
    <org_study_id>Alofisel-4001</org_study_id>
    <secondary_id>2017-002491-10</secondary_id>
    <secondary_id>EUPAS31439</secondary_id>
    <nct_id>NCT04118088</nct_id>
  </id_info>
  <brief_title>A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula</brief_title>
  <official_title>Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn's Disease and Complex Perianal Fistula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Development Center Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim is to check the long term side effects of a repeat treatment of darvadstrocel&#xD;
      and to see if that treatment improves symptoms of Crohn's disease and complex perianal&#xD;
      fistula. Participants will attend 8 clinic visits and will receive 1 treatment of&#xD;
      darvadstrocel at the third visit. A magnetic resonance imaging (MRI) will be performed&#xD;
      several times during the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The biological being tested in this study is called darvadstrocel (Alofisel). This study is&#xD;
      examining the long-term safety and efficacy of a repeat dose of darvadstrocel in people who&#xD;
      have Crohn's disease and complex perianal fistula.&#xD;
&#xD;
      The study will enroll approximately 50 patients. Participants will be assigned to one&#xD;
      treatment group to receive:&#xD;
&#xD;
      â€¢ Darvadstrocel 120 million cells&#xD;
&#xD;
      All participants would be allowed to receive one repeat dose of darvadstrocel in the whole&#xD;
      study. This multi-center trial will be conducted worldwide. The overall time to participate&#xD;
      in this study is approximately 3 years. Participants will make multiple visits to the clinic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with at Least 1 Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>From administration of repeat dose up to 156 weeks post-repeat administration</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an AE with an onset that occurs after receiving study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with at Least 1 Treatment Emergent Serious Adverse Event (TESAE)</measure>
    <time_frame>From administration of repeat dose up to 156 weeks post-repeat administration</time_frame>
    <description>An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Special Situation Reports (SSRs)</measure>
    <time_frame>From administration of repeat dose up to 156 weeks post-repeat administration</time_frame>
    <description>An SSR includes pregnancy, any case in which a pregnant participant is exposed to a study product or in which a female participant or female partner of a male participant becomes pregnant following treatment with a study product. Exposure is considered either through maternal exposure or via semen following paternal exposure or infant exposure from breast milk.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Event of Special Interest (AESI)</measure>
    <time_frame>From administration of repeat dose up to 156 weeks post-repeat administration</time_frame>
    <description>AESI includes immunogenicity/alloimmune reactions, hypersensitivity, transmission of infectious agents, tumorgenicity (applying to malignant tumors only), ectopic tissue formation, medication errors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Combined Remission of Perianal Fistula(s)</measure>
    <time_frame>At Week 24 and at Week 156 post-repeat darvadstrocel administration</time_frame>
    <description>Combined remission is defined as the closure of all treated external openings that were draining at baseline, despite gentle finger compression and absence of collection(s) &gt;2 cm (in at least 2 dimensions) of the treated perianal fistula(s) confirmed by central magnetic resonance imaging (MRI) assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Clinical Remission</measure>
    <time_frame>At Weeks 6, 24, 52, 104, and 156 post-repeat darvadstrocel administration</time_frame>
    <description>Clinical remission is defined as closure of all treated external fistula openings that were draining at baseline despite gentle finger compression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Clinical Response</measure>
    <time_frame>At Weeks 6, 24, 52, 104, and 156 post-repeat darvadstrocel administration</time_frame>
    <description>Clinical response is defined as closure of at least 50% of all treated external fistula openings that were draining at baseline despite gentle finger compression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Relapse From Week 24 Combined Remission</measure>
    <time_frame>From Week 24 to Week 156 post-repeat darvadstrocel administration</time_frame>
    <description>Relapse is defined as reopening of any of the treated fistula(s) external openings with active drainage as clinically assessed that were in the combined remission at Week 24 or the development of a collection &gt;2 cm (in at least 2 dimensions) of the treated perianal fistula(s) confirmed by centrally read MRI assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Relapse</measure>
    <time_frame>From Week 24 to the Day of relapse post-repeat darvadstrocel administration</time_frame>
    <description>Time to Relapse is defined as the time in days to reopening of any of the treated fistula(s) external openings with active drainage as clinically assessed, relative to Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with New Perianal Abscess in Treated Fistula</measure>
    <time_frame>Up to Week 156 post-repeat darvadstrocel administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Score of Discharge and Pain Items of Perianal Disease Activity Index (PDAI) Score</measure>
    <time_frame>Baseline to Weeks 6, 24, 52, 104, and 156 post-repeat darvadstrocel administration</time_frame>
    <description>The PDAI is a scoring system to evaluate the severity of perianal lesion associated with Crohn's disease. It includes the following 5 items: (a) discharge; (b) pain; (c) restriction of sexual activity; (d) type of perianal disease; and (e) degree of induration. Each item is graded on a 5-point scale ranging from no symptoms (score of 0) to severe symptoms (score of 4) and total range of score is from 0 to 20. Higher score means more severe disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Complex Perianal Fistula</condition>
  <arm_group>
    <arm_group_label>Darvadstrocel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have previously received darvadstrocel would receive a single repeat dose of darvadstrocel 120 million cells (5 million cells/mL), by local injection into the fistula.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Darvadstrocel</intervention_name>
    <description>Darvadstrocel suspension of human expanded adipose stem cells.</description>
    <arm_group_label>Darvadstrocel</arm_group_label>
    <other_name>Alofisel</other_name>
    <other_name>Cx601</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. In the opinion of the investigator, the participant is capable of understanding and&#xD;
             complying with protocol requirements.&#xD;
&#xD;
          2. The participant signs and dates a written, informed consent form (ICF) and any&#xD;
             required privacy authorization before the initiation of any study procedures.&#xD;
&#xD;
          3. The participant is male or female and aged 18 years or older.&#xD;
&#xD;
          4. The participant has complex perianal fistula(s) with a maximum of 2 internal openings&#xD;
             and a maximum of 3 external openings based on clinical assessment and a reading of a&#xD;
             locally-performed contrast enhanced (gadolinium) pelvic MRI. Fistula(s) must have been&#xD;
             draining for at least 6 weeks prior to baseline visit. A complex perianal fistula is&#xD;
             defined as a fistula that meets 1 or more of the following criteria:&#xD;
&#xD;
               1. High inter-sphincteric, high trans-sphincteric, extra-sphincteric or&#xD;
                  suprasphincteric.&#xD;
&#xD;
               2. Presence of â‰¥2 external openings.&#xD;
&#xD;
               3. Associated perianal abscess(es). Note: Abscesses that are larger than 2 cm in at&#xD;
                  least 2 dimensions on MRI must be confirmed to have been drained adequately by&#xD;
                  the surgeon during the preparation curettage in order to be eligible.&#xD;
&#xD;
          5. The participant has already received treatment with darvadstrocel for a complex&#xD;
             perianal fistula at least 6 months prior to baseline visit for retreatment, and their&#xD;
             physician has planned a repeat treatment administration for the original tract (full&#xD;
             remission not obtained or relapse of fistula draining) or for a new complex perianal&#xD;
             fistula tract.&#xD;
&#xD;
          6. The participant has controlled or mildly active CD (defined as patient reported&#xD;
             outcomes measure derived from CDAI patient reported outcome score-2 [PRO-2] score&#xD;
             &lt;14).&#xD;
&#xD;
          7. A male participant who is nonsterilized and sexually active with a female partner of&#xD;
             childbearing potential agrees to use barrier method of contraception (e.g. condom with&#xD;
             or without spermicide) from signing of informed consent and until 1 year after repeat&#xD;
             administration.&#xD;
&#xD;
          8. A female participant of childbearing potential who is sexually active with a&#xD;
             nonsterilized male partner agrees to use a highly effective/effective method of&#xD;
             contraception from signing of informed consent and until 1 year after repeat&#xD;
             administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The participant has lack of clinical response to prior treatment with darvadstrocel,&#xD;
             where clinical response is defined as closure of at least 50% of all treated external&#xD;
             fistula openings that were draining at baseline despite gentle finger compression or&#xD;
             in the case of a unique fistula, a partial closure of the fistula.&#xD;
&#xD;
          2. The participant has a history of hypersensitivity or allergies to darvadstrocel or&#xD;
             related compounds.&#xD;
&#xD;
          3. The participant has a history of hypersensitivity or allergies to penicillin or&#xD;
             aminoglycosides; Dulbecco modified eagle medium; bovine serum; local anesthetics or&#xD;
             gadolinium.&#xD;
&#xD;
          4. The participant is currently participating in a double-blind clinical study with&#xD;
             darvadstrocel. Participants participating in the ongoing INSPIRE registry&#xD;
             (Alofisel-5003) study would need to withdraw from that study in order to enroll in&#xD;
             this study.&#xD;
&#xD;
          5. The participant is currently receiving or has received any other investigational&#xD;
             medicinal product (IMP) within the last 3 months or at least 5 times the respective&#xD;
             elimination half-life time, whichever is longer, before signing the ICF.&#xD;
&#xD;
          6. The participant has known or suspected COVID-19 by the investigator within the past 2&#xD;
             months (additional testing may be performed at the discretion of the investigator).&#xD;
             Positive antibody testing for COVID without other evidence of current or recent active&#xD;
             infection does not exclude participation.&#xD;
&#xD;
             a) Participants who were in screening at the time that COVID 19-related factors&#xD;
             resulted in discontinuation may also be rescreened with approval of the sponsor or&#xD;
             designee.&#xD;
&#xD;
          7. The participant has major alterations in any of the following laboratory tests:&#xD;
&#xD;
               1. Serum creatinine levels &gt;1.5 times the upper limit of normal (ULN).&#xD;
&#xD;
               2. Total bilirubin &gt;1.5 Ã— ULN.&#xD;
&#xD;
               3. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;3.0 Ã— ULN.&#xD;
&#xD;
               4. Hemoglobin &lt;10.0 g/dL.&#xD;
&#xD;
               5. Platelets &lt;75.0 Ã— 109/L.&#xD;
&#xD;
               6. Albumin &lt;3.0 g/dL.&#xD;
&#xD;
          8. The participant has an increased risk for surgical procedure.&#xD;
&#xD;
          9. The participant has a known chronically active hepatopathy of any origin, including&#xD;
             cirrhosis and participants with persistent positive hepatitis B surface antigen and&#xD;
             quantitative hepatitis B virus polymerase chain reaction (PCR) or positive serology&#xD;
             for hepatitis C virus (HCV) and quantitative HCV PCR within 6 months before the&#xD;
             baseline visit.&#xD;
&#xD;
         10. If female, the participant is pregnant or breastfeeding, or intending to become&#xD;
             pregnant before participating in this study, during the study, or intending to donate&#xD;
             ova during such time period.&#xD;
&#xD;
         11. If male, the participant intends to donate sperm during this study.&#xD;
&#xD;
         12. The participant has a contraindication to MRI scan (e.g., due to the presence of&#xD;
             pacemaker, hip replacement, severe claustrophobia, or renal insufficiency as defined&#xD;
             by local clinical guidelines).&#xD;
&#xD;
         13. The participant has a contraindication to the anesthetic procedure.&#xD;
&#xD;
         14. The participant has severe rectal and/or anal stenosis that would make it impossible&#xD;
             to follow the surgery procedure.&#xD;
&#xD;
         15. The participant has severe proctitis (rectal ulcers &gt;0.5 cm) that would make it&#xD;
             impossible to follow the surgery procedure.&#xD;
&#xD;
         16. The participant has any prior invasive malignancy diagnosed within the last 3 years&#xD;
             before baseline visit. Participants with basal cell carcinoma of the skin completely&#xD;
             resected outside the perineal region can be included.&#xD;
&#xD;
         17. The participant has a current or recent (within 6 months before the baseline visit)&#xD;
             history of severe, progressive, and/or uncontrolled hepatic, hematologic,&#xD;
             gastrointestinal (other than CD), renal, endocrine, pulmonary, cardiac, neurologic, or&#xD;
             psychiatric disease that may result in participant's increased risk from study&#xD;
             participation and/or lack of compliance with study procedures.&#xD;
&#xD;
         18. The participant has had major surgery of the gastrointestinal tract within 6 months&#xD;
             before baseline or any minor surgery of the gastrointestinal tract 3 months before&#xD;
             baseline.&#xD;
&#xD;
         19. The participant had local major perianal surgery, and/or treatment with darvadstrocel&#xD;
             within 6 months before baseline. The abscess drainage, cleaning surgery, or seton&#xD;
             placement are not considered as &quot;local major surgery&quot; in this protocol.&#xD;
&#xD;
         20. The participant does not wish to or cannot comply with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Contact</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Akh Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+43 1 40400 4740</phone>
      <email>walter.reinisch@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Walter Reinisch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NH Hospital a.s.</name>
      <address>
        <city>Horovice</city>
        <state>Beroun</state>
        <zip>268 31</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+420 311553031</phone>
      <email>sercl@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Zuzana Serclova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hopital de l'Archet II - Gastro-Enterologie, Hepatologi</name>
      <address>
        <city>Nice cedex 03</city>
        <state>Alpes-Maritimes</state>
        <zip>6202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>330492036168</phone>
      <email>hebuterne.x@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Hebuterne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital de Pontchaillou - Maladies De L'Appareil Digesti</name>
      <address>
        <city>Rennes</city>
        <state>Ille-et-Vilaine</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>332 99 28 43 1186878</phone>
      <email>laurent.siproudhis@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent Siproudhis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Claude Huriez - Gastroenterologie</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33 3 20 44 47 14</phone>
      <email>maria.nachury@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Maria Nachury</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>AMIENS cedex 1</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33 3 22 08 88 50</phone>
      <email>fumery.mathurin@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Mathurin Fumery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud - Gastroenterology</name>
      <address>
        <city>Pierre-Benite</city>
        <state>Rhone</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33478861289</phone>
      <email>stephane.nancey@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Stephane Nancey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris St. Joseph Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33 (0) 145454692</phone>
      <email>v.deparades@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent De Parades</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33 1 44 64 20 64</phone>
      <email>etienney.i@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Etienny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Dresden, University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+493514582986</phone>
      <email>renate.schmelz@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Renate Schmelz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtisches Klinikum Luneburg</name>
      <address>
        <city>Luneburg</city>
        <state>Schleswig-Holstein,</state>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+49 4131 77 22 41</phone>
      <email>torsten.kucharzik@klinikum-lueneburg.de</email>
    </contact>
    <investigator>
      <last_name>Torsten Kucharzik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>493084454708</phone>
      <email>britta.siegmund@charite.de</email>
    </contact>
    <investigator>
      <last_name>Britta Siegmund</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Waldfriede</name>
      <address>
        <city>Berlin</city>
        <zip>14163</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+49 30 81 810-8509</phone>
      <email>c.buening@waldfriede.de</email>
    </contact>
    <investigator>
      <last_name>Carsten Buning</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+97226776848</phone>
      <email>erang@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Eran Goldin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organization, Hadassah Medical Center, Ein-Karem</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>972-2-6776848</phone>
      <email>klior@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Lior Katz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>97239372271</phone>
      <email>ian.white@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Ian White</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>9723-6973315</phone>
      <email>hagitt@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Hagit Tulchinsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chaim sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+972-54-6761898</phone>
      <email>lior.segev@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Lior Segev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>331834</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 871-205-500</phone>
      <email>xavier.gonzalez@ssib.es</email>
    </contact>
    <investigator>
      <last_name>Francisco Gonzalez Argente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Senora de la Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Canarias,</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>34 922 51 42 03</phone>
      <email>milvelillas@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Maria Vela Gonzalez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Donostia</name>
      <address>
        <city>Donostia</city>
        <state>San Sebastian</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>34943007173</phone>
      <email>anaisabel.munagorrisantos@osakidetza.eus</email>
    </contact>
    <investigator>
      <last_name>Ana Munagorri Santos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 932746222</phone>
      <email>fcasella@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Francesc Casellas Jorda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34932275400 ext 2779</phone>
      <email>ericart@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Elena Ricart Gomez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>8907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>34 93 260 76 23</phone>
      <email>tgolda@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Thomas Golda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 91 550 4800</phone>
      <email>dolores.herreros@quironsalud.es</email>
    </contact>
    <investigator>
      <last_name>Maria Delores Herreros Marcos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 91 727 7467</phone>
      <email>mmartinarranz@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Maria Delores Martin Arranz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34986800907</phone>
      <email>daniel.carpio.lopez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Daniel Carpio Lopez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H.C.U. de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 963862600</phone>
      <email>puchades_laulan@gva.es</email>
    </contact>
    <investigator>
      <last_name>Miguel Minguez Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 96 124 4000 Ext:440425</phone>
      <email>belenbeltranniclos@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Belen Beltran Niclos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2019</study_first_submitted>
  <study_first_submitted_qc>October 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Rectal Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

